Skip to content
Cultural Foundation
Author:
Veloxis Pharmaceuticals, Inc
Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress
June 17, 2026
Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients
April 22, 2026
Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology
March 30, 2026